Cited by 174Clostridium difficile and Clostridium perfringens researchProbiotics and Fermented FoodsGut microbiota and health

Treatment and prevention of antibiotic associated diarrhea

Bergogne-Bérézin, E·2000·International Journal of Antimicrobial Agents

Abstract

Mild or severe episodes of antibiotic-associated diarrhea (AAD) are common side effects of antibiotic therapy. The incidence of AAD differs with the antibiotic and varies from 5 to 25%. The major form of intestinal disorders is the pseudomembranous colitis associated with Clostridium difficile which occurs in 10-20% of all AAD. In most cases of AAD discontinuation or replacement of the inciting antibiotic by another drug with lower AAD risk can be effective. For more severe cases involving C. difficile, the treatment of diarrhea requires an antibiotic treatment, with glycopeptides (vancomycin) or metronidazole. Another approach to AAD treatment or prevention is based on the use of non-pathogenic living organisms, capable of re-establishing the equilibrium of the intestinal ecosystem. Several organisms have been used in treatment or prophylaxis of AAD such as selected strains of Lactobacillus acidophilus, L. bulgaricus, Bifidobacterium longum, and Enterococcus faecium. Another biotherapeutic agent, a non-pathogenic yeast, Saccharomyces boulardii has been used. In animal models of C. difficile colitis initiated by clindamycin, animals treated with S. boulardii (at end of vancomycin therapy) had a significant decrease in C. difficile colony-forming units, and of toxin B production. In several clinical randomised trials (versus placebo), S. boulardii has demonstrated its effectiveness by decreasing significantly the occurrence of C. difficile colitis and preventing the pathogenic effects of toxins A and B of C. difficile. It has been shown to be a safe and effective therapy in relapses of C. difficile colitis. A good response has been seen in children with AAD, treated by S. boulardii only. In ICUs prevention of AAD remains based on limitation of antibiotic overuse and spread of C. difficile or other agents of AAD should be prevented by improved hygiene measures (single rooms, private bathrooms for patients, use of gloves and hand washing for personnel). In addition the increasing use of biotherapeutic agents such as S. boulardii should permit the prevention of the major side effect of antibiotics, i.e. AAD in at risk patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0924-8579(00)00293-4

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 27 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Bergogne-Bérézin, E.
Affiliations
Université Paris Diderot (FR)
Corresponding author
Bergogne-Bérézin, E
Venue
International Journal of Antimicrobial Agents
Publisher
Elsevier BV
Published
2000-12
Volume
16
Issue
4
Pages
521-526
ISSN
0924-8579 (ISSN-L)
OpenAlex
W2065697342
Cited by
174
References
27
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 7 · 2020: 1 · 2019: 4 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 5 · 2014: 13 · 2013: 14 · 2012: 8
FWCI
4.36
Type
journal article
Language
en
Open access
closed
Locations
  • International Journal of Antimicrobial Agents (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
antibiotic-associated diarrhea, Clostridium difficile, pseudomembranous colitis, Saccharomyces boulardii, probiotics, vancomycin, metronidazole, Lactobacillus, Bifidobacterium longum, Enterococcus faecium, clindamycin, antibiotic overuse, infection control, toxin A and B, childhood diarrhea
MeSH terms
Anti-Bacterial Agents, Diarrhea, Enterocolitis, Pseudomembranous, Humans, Intestines, Lacticaseibacillus casei, Risk Factors, Saccharomyces, Clostridioides difficile, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review